Scholars@Duke

In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding.

Publication ,  Journal Article
Lopes, RD; Garcia, DA
Published in: Evid Based Med
December 2011
Published version (DOI) Link to item

Duke Scholars

Renato Delascio Lopes
Author Renato Delascio Lopes Medicine, Cardiology

Published In

Evid Based Med

DOI

10.1136/ebm.2011.0023

EISSN

1473-6810

Publication Date

December 2011

Volume

16

Issue

6

Start / End Page

187 / 188

Location

England

Related Subject Headings

  • General & Internal Medicine
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lopes, R. D., & Garcia, D. A. (2011). In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding. Evid Based Med, 16(6), 187–188. https://doi.org/10.1136/ebm.2011.0023
Lopes, Renato D., and David A. Garcia. “In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding.” Evid Based Med 16, no. 6 (December 2011): 187–88. https://doi.org/10.1136/ebm.2011.0023.
Lopes, Renato D., and David A. Garcia. “In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding.” Evid Based Med, vol. 16, no. 6, Dec. 2011, pp. 187–88. Pubmed, doi:10.1136/ebm.2011.0023.

Published In

Evid Based Med

DOI

10.1136/ebm.2011.0023

EISSN

1473-6810

Publication Date

December 2011

Volume

16

Issue

6

Start / End Page

187 / 188

Location

England

Related Subject Headings

  • General & Internal Medicine
  • 3202 Clinical sciences
  • 1103 Clinical Sciences